Johnson & Johnson
CompanyUnited StatesROR
Johnson & Johnson develops 8 assets, the furthest approved (canagliflozin in albuminuria). Mostly small molecule and device acting on AMPK signalling, Insulin/IGF-1 signalling and mTOR signalling; based in the United States.
- Assets
- 8
- Furthest
- Approved
- Trials
- 189
- Signals
- 1
Pipeline
8Sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion.
ApprovedSmall moleculeAMPK signallingInsulin/IGF-1 signallingalbuminuriacardiovascular death
Activates AMPK and reduces hepatic gluconeogenesis
ApprovedSmall moleculeMitochondrial biogenesis (PGC-1α)AMPK signallingtype 2 diabetesaging (Phase 3)
Nicotinic acetylcholine receptor agonist
ApprovedSmall moleculeCHRNA4CHRNB2smokingsmoking cessation
5 more assets
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials312
- Signals11
- Integrity notices5
- Similar companies6
Updated 7 Oct 2026 · 192 sources